The R&D window during an outbreak is very short; in some cases, there is only a limited number of patients for experimental treatment.

Pharmaceutical sponsors will struggle to complete the R&D of vaccines and treatments against global health biothreats in outbreak settings until they leverage lessons learned and decisive actions to overcome practical difficulties of R&D in an outbreak setting.

In this part-2 episode, I’ll explain additional key factors that led to R&D successes during the 2014-15 Ebola virus outbreak in West Africa. If you haven’t watched the part-1 video, I’ve included the link in the description below.

Watch PART 1 Video Now

*******

Hi, I'm Dr. Amos Ndhere! I am a medical doctor, Clinical Investigator, and Regulatory Affairs Specialist.

My goal is simple: Help Pharma industry leaders understand key trends, top strategies, and tools to conduct R&D in emerging markets and deliver life-changing treatments to patients faster.

*******

Do you want to deliver your clinical trial in sub-Saharan Africa safely?

Let's talk

*******

PS - Join the conversation on social!

⁠LinkedIn⁠

⁠Twitter⁠

⁠YouTube